NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Leap Therapeutics Inc (NASDAQ:LPTX) released its earnings results on Thursday, November, 14th. The company reported ($0.33) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.33). View Leap Therapeutics' Earnings History.

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics.

2 Wall Street analysts have issued 12-month target prices for Leap Therapeutics' stock. Their forecasts range from $3.25 to $5.00. On average, they anticipate Leap Therapeutics' stock price to reach $4.13 in the next twelve months. This suggests a possible upside of 418.6% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

News articles about LPTX stock have been trending extremely positive on Saturday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Leap Therapeutics earned a news impact score of 4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Leap Therapeutics.

Leap Therapeutics saw a decline in short interest in October. As of October 15th, there was short interest totalling 1,480,000 shares, a decline of 20.0% from the September 15th total of 1,850,000 shares. Based on an average daily volume of 298,000 shares, the days-to-cover ratio is presently 5.0 days. Approximately 10.4% of the shares of the company are short sold. View Leap Therapeutics' Current Options Chain.

Some companies that are related to Leap Therapeutics include Otonomy (OTIC), ASLAN PHARMACEU/ADR (ASLN), ESSA Pharma (EPIX), Synlogic (SYBX), Selecta Biosciences (SELB), Neos Therapeutics (NEOS), Immunic (IMUX), Vaccinex (VCNX), Elite Pharmaceuticals (ELTP), Infinity Pharmaceuticals (INFI), Marinus Pharmaceuticals (MRNS), Chembio Diagnostics (CEMI), Tiziana Life Sciences (TLSA), Aclaris Therapeutics (ACRS) and Catabasis Pharmaceuticals (CATB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Baidu (BIDU), Omeros (OMER) and Pieris Pharmaceuticals (PIRS).

Leap Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.10%). View Institutional Ownership Trends for Leap Therapeutics.

LPTX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Leap Therapeutics.

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LPTX stock can currently be purchased for approximately $0.80.

Leap Therapeutics has a market capitalization of $19.24 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

The official website for Leap Therapeutics is http://www.leaptx.com/.

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.